This study is for women with advanced cervical cancer. It tests two medications: pembrolizumab, which helps the immune system fight cancer, and lenvatinib, which may stop blood vessels from feeding tumors. The goal is to see how well these drugs work together. This is a phase II trial, which means it's still in early testing but shows promise in the lab.

The trial has two stages. In the first stage, 11 women will participate. If 2 or more respond well, 24 more will join for a total of 35. The trial will check how many respond positively. If 9 or more out of 35 show improvement, the treatment will be studied further.

• Participants must be women aged 18 or older with advanced cervical cancer that didn't respond to other treatments.
• Participants must not be pregnant or breastfeeding and have certain health conditions.
• The study requires regular visits and tests to monitor health and treatment effects.